Journal article
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Abstract
BACKGROUND: Full- or lower-dose anticoagulant therapy or aspirin can be used for extended therapy in patients with venous thromboembolism (VTE), but information on their relative benefit-risk profiles is limited.
METHODS: Data from the EINSTEIN-CHOICE trial were used to compare the benefit-risk profiles of extended treatment with rivaroxaban (20 or 10 mg once daily) and aspirin (100 mg once daily) in VTE patients who had completed 6 to …
Authors
Prandoni P; Lensing AWA; Prins MH; Gebel M; Pap AF; Homering M; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Cohen AT
Journal
Thrombosis Research, Vol. 168, , pp. 121–129
Publisher
Elsevier
Publication Date
August 2018
DOI
10.1016/j.thromres.2018.06.009
ISSN
0049-3848